Arvin Yang - Nov 30, 2022 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)

Role
Chief Medical Officer
Signature
/s/ Alejandra Carvajal, as Attorney-in-Fact
Stock symbol
MRSN
Transactions as of
Nov 30, 2022
Transactions value $
-$36,423
Form type
4
Date filed
12/2/2022, 03:01 PM
Previous filing
Jan 19, 2022
Next filing
Jan 18, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRSN Common Stock Options Exercise $0 +18.5K +142.6% $0.00 31.5K Nov 30, 2022 Direct F1
transaction MRSN Common Stock Sale -$36.4K -5.53K -17.56% $6.59* 25.9K Dec 1, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRSN Restricted stock unit Options Exercise $0 -18.5K -100% $0.00* 0 Nov 30, 2022 Common Stock 18.5K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on November 30, 2020.
F2 Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $6.38 to $6.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 Each RSU represents the contingent right to receive one share of common stock of the Issuer.
F5 The restricted stock units vested in full November 30, 2022.

Remarks:

Exhibit 24 - Power of Attorney